Impact of imatinib rechallenge on health-related quality of life in patients with TKI-refractory gastrointestinal stromal tumours: Sub-analysis of the placebo-controlled, randomised phase III trial (RIGHT)-Reference-Cited by-同舟云学术

Impact of imatinib rechallenge on health-related quality of life in patients with TKI-refractory gastrointestinal stromal tumours: Sub-analysis of the placebo-controlled, randomised phase III trial (RIGHT)

Published:2016-01 Issue: Volume:52 Page:201-208
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Yoo Changhoon^ORCID,Ryu Min-Hee,Nam Byung-Ho,Ryoo Baek-Yeol,Demetri George D.,Kang Yoon-Koo

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference15 articles.

1. Gastrointestinal stromal tumour;Joensuu;Lancet,2013

2. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors;Demetri;N Engl J Med,2002

3. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT;Blanke;J Clin Oncol,2008

4. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial;Demetri;Lancet,2006

5. Phase II study of dovitinib in patients with metastatic and/or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib;Kang;Br J Cancer,2013

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A case-matched study of imatinib mesylate between different formulations on plasma trough concentration, adverse events, quality of life and outcomes in gastrointestinal stromal tumor patients;PLOS ONE;2024-05-14

2. A randomised phase 2 study of continuous or intermittent dosing schedule of imatinib re-challenge in patients with tyrosine kinase inhibitor-refractory gastrointestinal stromal tumours;British Journal of Cancer;2023-05-13

3. Patient-reported outcomes in individuals with advanced gastrointestinal stromal tumor treated with ripretinib in the fourth-line setting: analysis from the phase 3 INVICTUS trial;BMC Cancer;2022-12-13

5. Treatment of Metastatic Gastrointestinal Stromal Tumors (GIST): A Focus on Older Patients;Drugs & Aging;2021-03-02